Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Young-Jin Kim, a director of Rezolute , Inc. (NASDAQ:RZLT), recently purchased 1,230,769 common shares of the company at a price of $3.25, in a transaction valued at $3.99 million. The purchase comes as the stock trades at $4.08, with analysts setting price targets between $9 and $15. According to InvestingPro analysis, RZLT currently appears fairly valued, with strong liquidity metrics including a current ratio of 8.43.
Following the transaction, the total number of common shares held indirectly by Handok, Inc. is 8,423,386. Kim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest. Kim also directly owns 149,950 shares. The company, with a market capitalization of $352.51 million, has shown strong returns over recent months. Discover more insights about RZLT and access comprehensive analysis with InvestingPro's detailed research report, one of 1,400+ available for top US stocks.
In other recent news, Rezolute, Inc. announced a public offering expected to raise approximately $90 million, involving over 20 million shares of common stock and pre-funded warrants. The funds are earmarked for research, development, and general corporate expenses. Additionally, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Rezolute's drug candidate, ersodetug, for treating hypoglycemia caused by tumor hyperinsulinism. This designation aims to accelerate the development of treatments for serious conditions. Rezolute's sunRIZE trial, evaluating ersodetug for congenital hyperinsulinism, will proceed without changes, following a recommendation from the Independent (LON:IOG) Data Monitoring Committee. BTIG analyst Julian Harrison reaffirmed a Buy rating on Rezolute, maintaining a price target of $15, citing the completion of enrollment for the sunRIZE trial. The company also appointed Erik Harris to its Board of Directors, bringing his extensive biopharmaceutical experience to aid in the commercialization of Rezolute's lead programs. Rezolute plans to file a Biologics License Application for ersodetug in mid-2026, with anticipated market introduction in the following years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.